KMT2A and acute myeloid leukemia: Since the t (6; 11)-r AML is known to be a peculiar KMT2A-r subgroup (Balgobind et al., 2009; Pigazzi et al., 2011; Pession et al., 2013), we previously identified that thioridazine and PD98059 selectively reduced KMT2A-AF6 AML cell proliferation and described their mechanism of action (Manara et al., 2014a; Tregnago et al., 2020).